Posted by Michael Wonder on 09 Oct 2019
Health Canada approves Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma
8 October 2019 - Approval of the highly selective Bruton's tyrosine kinase inhibitor in mantle cell lymphoma marks AstraZeneca's entry into the treatment of blood cancers.
AstraZeneca Canada today announced the Health Canada approval of Calquence (acalabrutinib) as an oral therapy for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
A Notice of Compliance for Calquence was granted based on positive data from the ACE-LY-004 trial which demonstrated an 81% overall response rate for patients with relapsed or refractory MCL.
